Targets › PDCD1
226 programs from 147 companies in 2804 trials: 1798 Phase 2, 579 Phase 1, 367 Phase 3, 60 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. (UniProt, Q15116)
Open in Phaseline: the race on PDCD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Chen Xiaoping | PD-1 monoclonal antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 4 | HCC | Dec 2027 |
| Shanghai Pulmonary Hospital, Shanghai, China | PD-1/PD-L1 inhibitor PD-1/PD-L1 pathway inhibitor; anti-PD-1 or anti-PD-L1 monoclonal antibody | PDCD1, CD274 | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Oct 2028 |
| GSK | Dostarlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Colonic Neoplasms; Neoplasms, Colon … | Nov 2026 |
| Akeso | Cadonilimab (AK104) Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor | PDCD1, CTLA4 | Phase 3 | Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) … | Nov 2026 |
| Samsung Bioepis | Pembrolizumab (SB27) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Stage II | Nov 2026 |
| BeiGene | Tislelizumab (A317) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non Small Cell Lung Cancer; Urothelial Carcinoma; Non-small Cell Lung Cancer; MSI-H/dMMR Solid Tumors … | Nov 2026 |
| Merck & Co. (MSD) | Pembrolizumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Melanoma; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Head and Neck Neoplasms … | Nov 2026 |
| Innovent Biologics (Suzhou) | IBI363 Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with | PDCD1, IL2 | Phase 3 | Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma … | Nov 2026 |
| Bristol-Myers Squibb | Nivolumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Urothelial Cancer; Melanoma; Renal Cell Carcinoma; Metastatic Colorectal Cancer … | Nov 2026 |
| Shanghai Henlius Biotech | Serplulimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Extensive Stage Small Cell Lung Cancer; Limited-Stage Small Cell Lung Cancer; Non Small Cell Lung Cancer; Metastatic Colorectal Cancer … | Nov 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | VSV injection Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Hepatocellular Carcinoma (HCC); Anal Squamous Cell Carcinoma, Limited-stage; Esophageal Neoplasms; Esophagus Cancer … | Dec 2026 |
| Pfizer | Sasanlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Non-muscle Invasive Bladder Cancer; Urothelial Carcinoma Bladder; Metastatic Renal Cell Carcinoma; Advanced Clear Cell Renal Carcinoma (Ccrcc) | Dec 2026 |
| Amgen | ABP 234 PD-1 inhibitor (pembrolizumab biosimilar) | PDCD1 | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC); Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Dec 2026 |
| Qilu Pharmaceutical | Pembrolizumab (QL2107) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | NSCLC; Carcinoma, Non-Small-Cell Lung; Extensive-stage Small Cell Lung Cancer; Advanced Solid Tumor | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | Penpulimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Advanced Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma; Advanced Pancreatic Cancer; Nasopharyngeal Neoplasms … | Dec 2026 |
| Sichuan Baili Pharmaceutical | Tislelizumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Extensive-stage Small-cell Lung Cancer; Urothelial Carcinoma; Esophageal Squamous Cell Carcinoma | Dec 2026 |
| RemeGen | Toripalimab (JS001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Urothelial Carcinoma; Gastric Cancer; Breast Cancer; Biliary Tract Cancer (BTC) … | Dec 2026 |
| Gilead Sciences | Zimberelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer … | Dec 2026 |
| Guangzhou Gloria Biosciences | Zimberelimab (GLS-010) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Persistent, Recurrent, or Metastatic Cervical Cancer; Solid Tumor | Dec 2026 |
| Akeso | Penpulimab (AK105) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Nasopharyngeal Carcinoma | Dec 2026 |
| Chinese PLA General Hospital | Anti-PD-1 antibody PD-1 inhibitor | PDCD1 | Phase 3 | Ovarian Cancer; Solid Tumor, Adult | Dec 2026 |
| Johnson & Johnson (Janssen) | Cetrelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Urinary Bladder Neoplasms; Bladder Cancer; Prostatic Neoplasms, Castration-Resistant; Neoplasms … | Dec 2026 |
| BeOne Medicines | Tislelizumab (A317) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | B-cell Malignancies; Metastatic Gastric Adenocarcinoma; Advanced Esophageal Squamous Cell Carcinoma; Advanced Unresectable Gastric Adenocarcinoma … | Dec 2026 |
| Mabwell (Shanghai) Bioscience | Toripalimab (JS001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Urothelial Carcinoma; Advanced Urothelial Carcinoma | Dec 2026 |
| Biocad | Nivolumab (BCD-263) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Advanced Melanoma | Jan 2027 |
| University Hospital, Bordeaux | PD-1/PD-L1 ICI + VEGFR-TKI combination PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR, FLT1, FLT4 | Phase 3 | Metastatic Renal Cell Carcinoma | Jan 2027 |
| AstraZeneca | Volrustomig (MEDI5752) CTLA-4/PD-1 bispecific antibody | CTLA4, PDCD1, TIGIT | Phase 3 | Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma … | Jan 2027 |
| Celltrion | CT-P51 PD-1 inhibitor | PDCD1 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Feb 2027 |
| Regeneron Pharmaceuticals | Cemiplimab (REGN2810) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Melanoma; Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Non-Small Cell Lung Cancer … | Mar 2027 |
| AstraZeneca | AZD2936 (rilvegostomig) Anti-TIGIT/anti-PD-1 bispecific antibody | TIGIT, PDCD1 | Phase 3 | Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer … | Mar 2027 |
| mAbxience Research | MB11 PD-1 inhibitor (nivolumab biosimilar) | PDCD1 | Phase 3 | Advanced (Unresectable or Metastatic) Melanoma | Apr 2027 |
| Akeso | AK112 (Ivonescimab) Dual PD-1/TIGIT bispecific antibody | PDCD1, VEGFA | Phase 3 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) | May 2027 |
| Ono Pharmaceutical | Nivolumab (ONO-4538) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Gastric Cancer; Pan-tumor; Colorectal Cancer; Rhabdoid Tumor … | May 2027 |
| Jiangsu HengRui Medicine | camrelizumab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); Cervical Cancer … | May 2027 |
| Chinese PLA General Hospital | Chidamide PD-1 checkpoint inhibitor | HDAC, PDCD1 | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia (AML); Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma; Acute Monocytic Leukemia; Relapsed/Refractory Acute Myeloid Leukemia … | Jun 2027 |
| Tongji Hospital | Iparomlimab and Tuvonralimab (QL1706) Bispecific antibody targeting PD-1 and CTLA-4 | CTLA4, PDCD1 | Phase 3 | Ovarian Clear Cell Carcinoma; Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Jun 2027 |
| Sun Yat-sen University | PD-1 antibody Monoclonal antibody targeting PD-1 immune checkpoint | PDCD1 | Phase 3 | Hepatocellular Carcinoma; Nasopharyngeal Cancinoma (NPC) | Jun 2027 |
| Taiho Pharmaceutical | Zimberelimab (AB122) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Biliary Tract Cancer; Advanced or Metastatic Solid Tumor | Jun 2027 |
| Fudan University | Tilelizumab PD-1 inhibitor | PDCD1 | Phase 3 | Gastric Cancer | Jul 2027 |
| Lepu Biopharma | Pucotenlimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Recurrent or Metastatic Nasopharyngeal Carcinoma; Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumors; Hepatocellular Carcinoma … | Aug 2027 |
| mAbxience Research | MB12 PD-1 inhibitor | PDCD1 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Sep 2027 |
| BriaCell Therapeutics | Retifanlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Breast Cancer; Anatomic Stage IV Breast Cancer AJCC v8; Merkel Cell Carcinoma; Recurrent Glioblastoma … | Dec 2027 |
| Canadian Cancer Trials Group | PD-1 inhibitor PD-1 inhibitor | PDCD1 | Phase 3 | Unresectable/Metastatic Melanoma | Dec 2027 |
| Innovent Biologics (Suzhou) | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | MSI-H | Apr 2028 |
| Chipscreen Biosciences | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Colorectal Cancer | May 2028 |
| Fudan University | Carrelizumab PD-1 inhibitor | PDCD1 | Phase 3 | TNBC - Triple-Negative Breast Cancer | Jul 2028 |
| Sun Yat-sen University | PD-1/PD-L1 inhibitors PD-1 and PD-L1 checkpoint inhibitors | PDCD1, CD274 | Phase 3 | Non-small Cell Lung Cancer | Jul 2028 |
| Innovent Biologics (Suzhou) | Sindilizumab PD-1 inhibitor | PDCD1 | Phase 3 | Non-Small Cell Lung Cancer; SBRT; Colorectal Cancer Metastatic; Hepatoid Adenocarcinoma of Stomach | Oct 2028 |
| Taizhou Hanzhong biomedical | Pucotenlimab (HX008) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Metastatic Colorectal Cancer | Oct 2028 |
| Fudan University | PD-1 inhibitors PD-1 inhibitor | PDCD1 | Phase 3 | Esophageal Carcinoma | Oct 2028 |
| Hutchmed | sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| UNICANCER | Reduced dose intensity of IO Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor | PDCD1, CD274, CTLA4 | Phase 3 | Lung Cancer Metastatic | May 2029 |
| Sun Yat-sen University | PD-1/PD-L1 immune checkpoint inhibitor PD-1/PD-L1 immune checkpoint inhibitor | PDCD1, CD274 | Phase 3 | Locally Advanced Non-Small Cell Lung Cancer | Jun 2029 |
| Peking Union Medical College Hospital | PD-1 inhibitors PD-1 pathway inhibitor | PDCD1 | Phase 3 | Cervical Cancer | Oct 2029 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Anti-PD-1/PD-L1 Antibody PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 3 | Esophagus Cancer; Esophageal Cancer | Dec 2030 |
| Ji Dongmei | Finotonlimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Squamous Cell Carcinoma of Head and Neck | Sep 2031 |
| CStone Pharmaceuticals | Cs-1003 (CS1003) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Hepatocellular Carcinoma | – |
| AbbVie | Budigalimab (ABBV-181) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 2 | Hepatocellular Carcinoma; Urothelial Carcinoma; Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Non-Small Cell Lung Cancer … | Nov 2026 |
| Sichuan Baili Pharmaceutical | SI-B003 PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer … | Nov 2026 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2868 injection Anti-PD-1/TGF-βRII bifunctional fusion protein | PDCD1, TGFBR2 | Phase 2 | Pancreatic Neoplasms | Nov 2026 |
| Bio-Thera Solutions | BAT1308 anti-PD-1 monoclonal antibody | PDCD1 | Phase 2 | Cervical Cancer; Advanced Solid Tumors | Nov 2026 |
| Beijing Tongren Hospital | Tislelizumab-jsgr PD-1 inhibitor | PDCD1 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Nov 2026 |
| Ruijin Hospital | PD-1 Inhibitor Programmed Death-1 (PD-1) inhibitor - intra-arterial administration | PDCD1 | Phase 2 | DLBCL; Pancreatic Neoplasms | Dec 2026 |
| RenJi Hospital | ABSK043 PD-1/PD-L1 interaction inhibitor | PDCD1, CD274 | Phase 2 | HCC - Hepatocellular Carcinoma | Dec 2026 |
| CrystalGenomics | Camrelizumab (SHR-1210) Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Non Squamous Non Small Cell Lung Cancer | Dec 2026 |
| Sichuan Baili Pharmaceutical | PD-1 Monoclonal Antibody PD-1 inhibitor | PDCD1 | Phase 2 | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma; Triple-negative Breast Cancer; Extensive-stage Small-cell Lung Cancer; Esophageal Cancer … | Dec 2026 |
| Navy General Hospital, Beijing | PD-1 therapy PD-1 inhibitor | PDCD1 | Phase 2 | Relapsed Classic Hodgkin Lymphoma | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | carrizumab PD-1 inhibitor | PDCD1 | Phase 2 | Tumor Immunity | Dec 2026 |
| Sir Run Run Shaw Hospital | Aiparolitoworixureli injection PD-1/CTLA-4 bispecific monoclonal antibody; dual checkpoint inhibitor blocking PD-1 and CT | PDCD1, CTLA4 | Phase 2 | Rectal Cancer | Dec 2026 |
| The Second Affiliated Hospital of Chongqing Medical University | Anti-PD-1 antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Chronic Hepatitis b | Dec 2026 |
| Li Zhang | Cardenilimab PD-1 inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2026 |
| Ruijin Hospital | Iparomlimab and Tuvonralimab (QL1706) PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Gastric Adenocarcinoma | Dec 2026 |
| Sichuan University | PD-1 Inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma; NSCLC | Dec 2026 |
| Xinqiao Hospital of Chongqing | PD-1 inhibitors PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | NSCLC Stage IV Without EGFR/ALK Mutation | Dec 2026 |
| Jiang Feng | PD-1 monoclonal antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Head and Neck Squamous Carcinoma | Dec 2026 |
| First Affiliated Hospital of Zhejiang University | PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection) PD-1/CTLA-4 dual checkpoint inhibitor antibody | PDCD1, CTLA4 | Phase 2 | Bile Duct Carcinoma | Dec 2026 |
| Shandong Provincial Hospital | QL1706 (Iparomlimab and Tuvonralimab) Combination of PD-1 inhibitor (Iparomlimab) and CTLA-4 inhibitor (Tuvonralimab) | PDCD1, CTLA4 | Phase 2 | Locally Advanced Resectable Esophageal Squamous Cell Carcinoma; Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Dec 2026 |
| Shenyang Sunshine Pharmaceutical | SSGJ-705 Anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid Tumors | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | anti-PD-1 or PD-L1 antibody PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Head and Neck Cancer | Dec 2026 |
| The Second Affiliated Hospital of Chongqing Medical University | anti-PD-1/anti-PD-L1 antibody PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Chronic Hepatitis B | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | PD-1/VEGF dual antibody PD-1 inhibitor and anti-VEGF antibody | PDCD1, VEGFA, CTLA4 | Phase 2 | Glioblastoma | Jan 2027 |
| Shanghai Chest Hospital | PD-1 inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinomas; Esophageal Squamous Cell Carcinoma | Jan 2027 |
| Tao Zhang | Pirfenidone PD-1 monoclonal antibody; immune checkpoint inhibitor | PDCD1 | Phase 2 | Colorectal Cancer (CRC) | Jan 2027 |
| Peking University Cancer Hospital & Institute | Adebelizumab PD-1 inhibitor | PDCD1 | Phase 2 | SCLC, Extensive Stage | Jan 2027 |
| Sichuan Cancer Hospital and Research Institute | Tirelizumab PD-1 inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma | Jan 2027 |
| University Health Network, Toronto | Opdualag (BMS-986213) Anti-LAG3/anti-PD-1 bispecific antibody | LAG3, PDCD1 | Phase 2 | Cutaneous Melanoma | Feb 2027 |
| Peking University Cancer Hospital & Institute | Tirelizumab PD-1 inhibitor | PDCD1 | Phase 2 | Collecting Duct Carcinoma | Feb 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | PD-1 monoclonal antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Gastric Cancer | Mar 2027 |
| Zhejiang Cancer Hospital | PD-1/PD-L1 inhibitors PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Adjuvant Radiotherapy | Mar 2027 |
| Peking University Cancer Hospital & Institute | QL1706 Anti-PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Esophageal Squamous Cell Carcinoma | Mar 2027 |
| Sun Yat-sen University | Triprolizumab PD-1 inhibitor | PDCD1 | Phase 2 | Adrenocortical Carcinoma | Mar 2027 |
| baotai Liang | Triprilizumab PD-1 monoclonal antibody | PDCD1 | Phase 2 | Prostate CA | Mar 2027 |
| Zhejiang Cancer Hospital | Cardunolizumab PD-1 inhibitor | PDCD1 | Phase 2 | Vulvar and Vaginal Cancer | Mar 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | PD-1 inhibitors PD-1/PD-L1 pathway inhibitor | PDCD1 | Phase 2 | SCLC | Mar 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | PD-1/PD-L1 inhibitors PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Advanced Malignant Solid Tumor | Apr 2027 |
| Sun Yat-sen University | Sinitilimab PD-1 monoclonal antibody | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | Apr 2027 |
| Peking University Third Hospital | Carilizumab PD-1 inhibitor | PDCD1 | Phase 2 | Gastric Cancer | Apr 2027 |
| Sun Yat-sen University | Iparomlimab and Tuvonralimab (QL1706) Dual PD-1/CTLA-4 combination antibody | CTLA4, PDCD1 | Phase 2 | Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer; Bone and Soft Tissue Tumors; BRAF V600 Colorectal Cancer; Hepatocellular Carcinoma (HCC) … | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | lparomlimab and Tuvonralimab Injection (QL1706) Anti-PD-1/CTLA-4 combined antibody | PDCD1, CTLA4 | Phase 2 | Endometrial Adenocarcinoma; Metastatic Pancreatic Cancer; HCC; Breast Cancer | Apr 2027 |
| Daihong Liu | PD-1 Inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | May 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aitua Combination Antibody (QL1706) PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | High-grade Serous Ovarian Cancer (HGSOC) | May 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Tirilizumab PD-1 inhibitor | PDCD1 | Phase 2 | Gastric Cancer, Metastatic | May 2027 |
| Shanghai Zhongshan Hospital | PD-1 Monoclonal Antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Intrahepatic Cholangiocarcinoma; Gastric Cancer | Jun 2027 |
| Novartis | Spartalizumab (PDR001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Advanced Solid Tumors; Squamous Cell Anal Carcinoma … | Jun 2027 |
| Tongji Hospital | PD-1 Inhibitor PD-1 checkpoint inhibitor (specific agent variable per institution: pembrolizumab, sintili | PDCD1 | Phase 2 | Solid Tumors; Hepotacellular Carcinoma | Jun 2027 |
| Dechang Diao | PD-1 Monoclonal Antibody PD-1 inhibitor | PDCD1 | Phase 2 | pMMR/MSS Locally Advanced Rectal Cancer; Short-course Radiotherapy Plus Chemotherapy | Jul 2027 |
| Xijing Hospital | Iparomlimab/Tuvonralimab (QL1706) Bispecific antibody targeting PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Locally Advanced Cervical Cancer | Jul 2027 |
| MacroGenics | Lorigerlimab Bispecific DART protein binding PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic Adenocarcinoma | Jul 2027 |
| Mabwell (Shanghai) Bioscience | PD-1 inhibitor PD-1 inhibitor | PDCD1 | Phase 2 | Triple-Negative Breast Cancer | Jul 2027 |
| Fudan University | PD-L1/PD-1 inhibitor and chemotherapy PD-L1/PD-1 checkpoint inhibitors combined with chemotherapy | PDCD1, CD274 | Phase 2 | NSCLC Stage IV | Jul 2027 |
| Daihong Liu | PD-1Ab21-BCMA CAR-T BCMA-targeting CAR-T cells secreting PD-1 antibody and interleukin-21 fusion protein | BCMA, PDCD1, IL21 | Phase 2 | Multiple Myeloma | Jul 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Anti-PD-1 inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Liver Transplantation | Aug 2027 |
| Ruijin Hospital | Apalulizumab Dual-function antibody targeting both PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Pancreatic Adenocarcinoma Locally Advanced | Aug 2027 |
| Ruijin Hospital | Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) Bispecific antibody targeting PD-1 and CTLA-4 immune checkpoints | PDCD1, CTLA4 | Phase 2 | Pancreatic Adenocarcinoma Locally Advanced | Aug 2027 |
| Hongmeng Yu | PD-1 / PD-L1 monoclonal antibody PD-1 inhibitor | PDCD1 | Phase 2 | Nasopharyngeal Carcinoma (NPC) | Aug 2027 |
| Fudan University | PD-1 antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma | Aug 2027 |
| Jinling Hospital, China | PD-1/PD-L1 ICI + VEGFR-TKI PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR | Phase 2 | Renal Cell Carcinoma (RCC) | Aug 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Ivonescimab (AK112) PD-1/PD-L2 dual checkpoint inhibitor | PDCD1L2, PDCD1 | Phase 2 | ESCC | Aug 2027 |
| Shenyang Sunshine Pharmaceutical | SSGJ-706 PD-1/PD-L1 bispecific antibody | PDCD1, CD274 | Phase 2 | First-line Advanced NSCLC Patients | Aug 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Tirellizumab PD-1 inhibitor monoclonal antibody | PDCD1 | Phase 2 | Oral Cancer; HNSCC | Aug 2027 |
| The First Affiliated Hospital of Zhengzhou University | cadonilizumab PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Esophageal Squamous Cell Carcinoma | Aug 2027 |
| Sixth Affiliated Hospital, Sun Yat-sen University | PD-1 monoclonal antibody PD-1 immune checkpoint inhibitor | PDCD1 | Phase 2 | Multiple Cancer | Sep 2027 |
| Agenus | Balstilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Advanced Melanoma; Metastatic Colorectal Cancer; Advanced Cancer; Gastric Cancer … | Sep 2027 |
| Arcus Biosciences | zimberelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 2 | Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer; Advanced Cancer; Clear Cell Renal Cell Carcinoma | Sep 2027 |
| Ming-Yuan Chen | Carrellimab PD-1 inhibitor (recombinant monoclonal antibody) | PDCD1 | Phase 2 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Sep 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Iparomlimab PD-1 and CTLA-4 inhibitor | PDCD1, CTLA4 | Phase 2 | Esophageal Cancer | Sep 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Iparomlimab and Tuvonralimab (QL1706) PD-1 and CTLA-4 dual checkpoint inhibitor | PDCD1, CTLA4 | Phase 2 | HCC - Hepatocellular Carcinoma | Oct 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Rilapafup α PD-1 inhibitor | PDCD1 | Phase 2 | Biliary Tract Cancer (BTC) | Oct 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Iparomlimab/Tuvonralimab Bifunctional mabpair product of anti-PD-1 and anti-CTLA-4 antibodies | PDCD1, CTLA4 | Phase 2 | LOCALLY ADVANCED CERVICAL CANCERS | Nov 2027 |
| Lei Liu | Ivonescimab Bispecific antibody targeting PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2027 |
| Nanfang Hospital, Southern Medical University | Iparomlimab and Tuvonralimab Injection (QL1706) PD-1 and CTLA-4 dual inhibitor | PDCD1, CTLA4 | Phase 2 | Hepatecellular Carcinoma | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Tiselizumab PD-1 inhibitor | PDCD1 | Phase 2 | Follicular Lymphoma | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Ivonescimab (AK112) Bispecific monoclonal antibody targeting PD-1 and VEGF | PDCD1, VEGFA | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2027 |
| Sixth Affiliated Hospital, Sun Yat-sen University | PD-1 inhibitor PD-1 receptor antagonist | PDCD1 | Phase 2 | Rectal Cancer; Neoadjuvant Therapies; Colon Cancer; Immune Checkpoint Therapy | Dec 2027 |
| Haitao Zhao, MD | PD-1 inhibitor PD-1 inhibitor | PDCD1 | Phase 2 | Biliary Tract Cancer (BTC) | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | PD-1 inhibitors Programmed death-1 pathway inhibitor | PDCD1 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Dec 2027 |
| Innovent Biopharmaceutical Technology (Hangzhou) | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Hepatocellular Carcinoma (HCC); Resectable Gastric/Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Squamous Cell Non-small Cell Lung Cancer … | Dec 2027 |
| TaiRx | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | HCC - Hepatocellular Carcinoma | Dec 2027 |
| Shandong Provincial Hospital | Tirelizumab PD-1 inhibitor | PDCD1 | Phase 2 | Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Dec 2027 |
| Bai-Rong Xia | Torvolumab PD-1 inhibitor antibody | PDCD1 | Phase 2 | Ovary Cancer | Dec 2027 |
| Chuangzhen Chen | PD-1/PD-L1 monoclonal antibodies PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Radiotherapy | Jan 2028 |
| CSPC Megalith Biopharmaceutical | Enlonstobart recombinant human anti-PD-1 monoclonal antibody | PDCD1 | Phase 2 | Ovarian Cancer; Head and Neck Squamous Cell Carcinoma | Apr 2028 |
| Shanghai Zhongshan Hospital | Iparomlimab and Tuvonralimab (QL1706) Bifunctional monoclonal antibody composed of PD-1 inhibitor (IgG4) and CTLA-4 inhibitor (I | PDCD1, CTLA4 | Phase 2 | Biliary Tract Cancer (BTC) | Jun 2028 |
| Shanghai Pulmonary Hospital, Shanghai, China | IBI363 PD-1/IL-2α biased agonist | PDCD1, IL2RA | Phase 2 | Unresectable Stage III Non-small Cell Lung Cancer | Jun 2028 |
| Regeneron Pharmaceuticals | REGN10597 PD-1-IL2Ra-IL2 immunotherapy | PDCD1, IL2RA, IL2 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Melanoma | Jun 2028 |
| Swiss Cancer Institute | Ivonescimab Bispecific PD-1/VEGF antibody | PDCD1, VEGFA | Phase 2 | NSCLC | Jul 2028 |
| Shandong Cancer Hospital and Institute | Iparomlimab/Tuvonralimab PD-1 inhibitor | PDCD1 | Phase 2 | Hepatocellular Carcinoma | Jul 2028 |
| Changhai Hospital | QL1706 Dual PD-1/CTLA-4 antibody | PDCD1, CTLA4 | Phase 2 | MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706 | Aug 2028 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Tirellizumab PD-1 inhibitor | PDCD1 | Phase 2 | Gastric Junction Adenocarcinoma | Aug 2028 |
| Tianjin Medical University Cancer Institute and Hospital | PD-1 antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Locally Advanced Gastric Adenocarcinoma | Aug 2028 |
| Obstetrics & Gynecology Hospital of Fudan University | Ivonescimab TIGIT inhibitor with bispecific antibody targeting TIGIT and PD-1 | PDCD1, CTLA4 | Phase 2 | Cervical Cancers | Aug 2028 |
| City of Hope Medical Center | Anti-PD1 Monoclonal Antibody PD-1 inhibitor | PDCD1 | Phase 2 | Lung Non-Small Cell Carcinoma | Oct 2028 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PD-1 inhibitors (extended-dose interval) PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Triple -Negative Breast Cancer | Dec 2028 |
| The First Affiliated Hospital with Nanjing Medical University | PD-1/PD-L1 monoclonal antibody PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 2 | Primary Central Nervous System Lymphoma (PCNSL) | Dec 2028 |
| Kong Fanming | pabolizumab PD-1 inhibitor | PDCD1 | Phase 2 | Non-Small Cell Lung Cancer | Dec 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | PD-1/PD-L1/CTLA-4 inhibitors PD-1, PD-L1, and CTLA-4 checkpoint inhibitors | PDCD1, CD274, CTLA4 | Phase 2 | Head/Neck Neoplasm | Jan 2029 |
| Ruijin Hospital | PD-1 antibody PD-1 pathway inhibition | PDCD1 | Phase 2 | Natural Killer/T-cell Lymphoma | Feb 2029 |
| Nanfang Hospital, Southern Medical University | EGFR-TKIs Combined with PD-1 Monoclonal Antibody EGFR tyrosine kinase inhibitor combined with PD-1 inhibitor | EGFR, PDCD1 | Phase 2 | Lung Cancer Non-Small Cell Cancer (NSCLC) | Mar 2029 |
| Guangxi Medical University | PD-1 inhibitor PD-1 inhibitor | PDCD1 | Phase 2 | Nasopharyngeal Carcinoma | Mar 2029 |
| Tianjin Medical University Second Hospital | PD-1/PD-L1 Inhibitor PD-1/PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Bladder (Urothelial, Transitional Cell) Cancer | Mar 2029 |
| Sixth Affiliated Hospital, Sun Yat-sen University | sintlimab PD-1 monoclonal antibody | PDCD1 | Phase 2 | Rectal Squamous Cell Carcinoma | Jun 2029 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Tirelizumab PD-1 inhibitor | PDCD1 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Feb 2030 |
| Fudan University | Anti-PD1 antibody PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Locally Recurrent Rectal Cancer | Mar 2030 |
| Virginia Commonwealth University | Anti-PD-1 immunotherapy PD-1 checkpoint inhibitor | PDCD1 | Phase 2 | Non-Small Cell Lung Cancer | Jul 2030 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Carrelizumab PD-1 inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2030 |
| UNC Lineberger Comprehensive Cancer Center | PD-1/PD-L1 inhibitor monotherapy PD-1 or PD-L1 checkpoint inhibitor | PDCD1, CD274 | Phase 2 | Lung Cancer | Jan 2033 |
| University of California, Davis | Systemic (ICI)-based therapy informed by PROphet CB assay and CARG-TT assessment anti-PD(L)1 immune checkpoint inhibitor(s), with regimen selection guided by proteomic (PR | PDCD1, CD274 | Phase 2 | Non-small Cell Lung Cancer Stage IIIC | May 2036 |
| Tongji Hospital | Cardonilizumab PD-1 inhibitor | PDCD1 | Phase 2 | Esophageal Squamous Cell Carcinoma | – |
| Hunan Province Tumor Hospital | IBI318 Bispecific anti-PD-1/PD-L1 antibody | PDCD1, CD274 | Phase 2 | Non-Small Cell Lung Cancer | – |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | PD-1 Antibody PD-1 inhibitor; checkpoint immunotherapy | PDCD1 | Phase 2 | Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer | – |
| AnaptysBio | Rosnilimab PD-1 agonist antibody | PDCD1 | Phase 2 | Rheumatoid Arthritis; Ulcerative Colitis | – |
| Shanghai Zhongshan Hospital | cardonilizumab PD-1 and CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 1 | Biliary Tract Cancer | Dec 2026 |
| Akeso | AK129 Bispecific antibody targeting LAG-3 and PD-1 | LAG3, PDCD1 | Phase 1 | Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin Lymphoma | Dec 2026 |
| Rottapharm Biotech | Balstilimab (AGEN2034) Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Refractory Metastatic Colorectal Cancer | Dec 2026 |
| Ruijin Hospital | PD-1 knockout TILs PD-1 gene knockout in tumor-infiltrating lymphocytes to enhance T cell anti-tumor activity | PDCD1 | Phase 1 | Colorectal Cancer (CRC) | Dec 2026 |
| Sunshine Guojian Pharmaceutical (Shanghai) | SSGJ-705 anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 1 | Locally Advanced, Recurrent or Metastatic Malignancies | Dec 2026 |
| L & L Bio Co., Ltd., Ningbo, China | LB1410 anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Solid Tumor | Dec 2026 |
| West China Hospital | PD-1 mRNA LNP Vaccine (Low Dose, 50 mcg) mRNA vaccine encoding PD-1, delivered via lipid nanoparticles | PDCD1 | Phase 1 | Malignant Tumors; Liver Cancer; Hepatocellular Carcinoma (HCC) | Dec 2026 |
| China-Japan Friendship Hospital | PD-1/L1 inhibitor PD-1/PD-L1 pathway inhibitor | PDCD1, CD274 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Sun Yat-sen University | SarcVac (Neoantigen vaccine) PD-1 checkpoint inhibitor | PDCD1 | Phase 1 | Soft Tissue Sarcoma (STS) | Dec 2026 |
| Peking Union Medical College Hospital | Cardonilizumab PD-1 inhibitor monoclonal antibody | PDCD1 | Phase 1 | Hepatocellular Carcinoma | Jan 2027 |
| Inge Marie Svane | TIL therapy with CRISPR PD-1 silencing CRISPR-Cas9 silencing of PD-1 gene in tumor infiltrating lymphocytes | PDCD1 | Phase 1 | Melanoma Metastatic | Jan 2027 |
| LigaChem Biosciences | Anti-PD-1 monoclonal antibody PD-1 inhibitor | PDCD1 | Phase 1 | Advanced Solid Tumors; Relapsed/Refractory Peripheral T-cell Lymphoma; Renal Cell Carcinoma; Solid Tumors … | Jan 2027 |
| Jiangsu Topcel-KH Pharmaceutical | Anti-PD1 armored CD19 CAR-T cells Anti-PD1 armored CD19 CAR-T cell therapy | CD19, PDCD1 | Phase 1 | Diffuse Large B Cell Lymphoma | Jan 2027 |
| Bio-Thera Solutions | Pembrolizumab (BAT3306) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| Sun Yat-sen University | WTX212A Erythrocyte-αPD-1 antibody conjugates | PDCD1 | Phase 1 | Solid Tumor Cancer | Feb 2027 |
| Johnson & Johnson (Janssen) | Cetrelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Carcinoma, Non-small-Cell Lung; Neoplasms | Apr 2027 |
| Sichuan Luzhou Buchang Biopharmaceutical | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Advanced or Metastatic Gastric Cancer | Apr 2027 |
| Shanghai Henlius Biotech | Pembrolizumab (HLX17) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Non-small Cell Lung Cancer | Apr 2027 |
| Shanghai Juncell Therapeutics | PD-1 antibody PD-1 inhibitor (low-dose) | PDCD1 | Phase 1 | Solid Tumor; Perihilar Cholangiocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); Lung Cancer | May 2027 |
| AstraZeneca | AZD7789 (sabestomig) anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLC | May 2027 |
| Beijing Tongren Hospital | Finotonlimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | HNSCC | Jun 2027 |
| OncoC4 | AI-081 Bispecific antibody targeting PD-1 and VEGF | PDCD1, VEGFA | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| Roche | RO7247669 Anti-PD-1 and anti-LAG-3 bispecific antibody | PDCD1, LAG3 | Phase 1 | Solid Tumors | Jun 2027 |
| West China Hospital | PD-1/PD-L1 Inhibitor-Based Therapy PD-1/PD-L1 inhibitor monotherapy or combination therapy | PDCD1, CD274 | Phase 1 | Solid Tumors | Jul 2027 |
| Shanghai Henlius Biotech | HLX18 PD-1 inhibitor | PDCD1 | Phase 1 | Esophageal and/or Cardia Cancer | Aug 2027 |
| Seqker Biosciences | anti-PD-1 immune checkpoint inhibitor PD-1 checkpoint inhibitor | PDCD1 | Phase 1 | Solid Tumors | Aug 2027 |
| Biocon Biologics UK | Bmab1700 PD-1 inhibitor (nivolumab biosimilar) | PDCD1 | Phase 1 | Melanoma | Aug 2027 |
| Memorial Sloan Kettering Cancer Center | M28z1XXPD1DNR CAR T cells Mesothelin-targeted CAR T cells with anti-PD1 component | MSLN, PDCD1 | Phase 1 | Malignant Pleural Mesothelioma (MPM); Mesothelin Positive | Sep 2027 |
| Shenyang Sunshine Pharmaceutical | SSGJ-709 Bispecific antibody targeting PD-1 and LAG-3 | PDCD1, LAG3 | Phase 1 | Advanced Malignant Tumors | Sep 2027 |
| Alvotech Swiss | AVT32-DRL_PB PD-1 inhibitor (pembrolizumab biosimilar) | PDCD1 | Phase 1 | Melanoma | Oct 2027 |
| Tianjin Medical University Cancer Institute and Hospital | GK01 cell injection PD-1 inhibitor | PDCD1 | Phase 1 | Solid Tumors; Advanced Solid Tumors | Dec 2027 |
| Biocon Biologics UK | Bmab1800 PD-1 inhibitor | PDCD1 | Phase 1 | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) | Dec 2027 |
| M.D. Anderson Cancer Center | Anti-PD-1/PD-L1 PD-1/PD-L1 checkpoint inhibitor monoclonal antibodies | PDCD1, CD274 | Phase 1 | Advanced Malignant Solid Neoplasm | Feb 2028 |
| Ono Pharmaceutical | ONO-4538HSC PD-1 inhibitor | PDCD1 | Phase 1 | Advanced or Metastatic Solid Tumors; Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | Feb 2028 |
| Immorna Biotherapeutics | JCXH-211 PD-1 checkpoint inhibitor | PDCD1 | Phase 1 | Malignant Solid Tumors | Mar 2028 |
| MabQuest | MAQ-001 Anti-PD-1 monoclonal antibody with alternative mechanism independent of PD-1/PD-L1 blockad | PDCD1 | Phase 1 | Advanced Solid Tumor | Jun 2028 |
| ImmVirx | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Colorectal Cancer | Jun 2028 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Pulse radiotherapy combined with PD(L)-1 inhibitors Pulsed radiotherapy combined with PD(L)-1 immune checkpoint inhibition | PDCD1, CD274 | Phase 1 | Non Small Cell Lung Cancer | Jul 2028 |
| Fundacio Clinic Barcelona | PD1+ TILs (NUMARZU-001) PD1-positive tumor-infiltrating lymphocytes (TILs) adoptive cell therapy | PDCD1 | Phase 1 | Metastatic Triple-Negative Breast Carcinoma | Sep 2028 |
| Akeso | AK131 anti-PD-1 and CD73 bispecific antibody | PDCD1, NT5E | Phase 1 | Solid Tumor | Dec 2028 |
| Ottimo Pharma | OTP-01 Dual paratopic PD-1/VEGFR2 antibody | PDCD1, KDR | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| Jiangsu Simcere Pharmaceutical | SIM0689 for Injection PD-1/VEGF bispecific antibody | PDCD1, VEGFA | Phase 1 | Neoplasms, Malignant | Dec 2028 |
| OSE Immunotherapeutics | OSE-279 PD-1 blocking monoclonal antibody | PDCD1 | Phase 1 | Solid Advanced Tumor | Dec 2029 |
| Vanderbilt-Ingram Cancer Center | nivolumab-IRDye800CW PD-1 inhibitor conjugated to near-infrared fluorescent dye for molecular imaging | PDCD1 | Phase 1 | Hnscc | Apr 2030 |
| Australian & New Zealand Children's Haematology/Oncology Group | Opdualag PD-1 and LAG-3 inhibitor combination | PDCD1, LAG3 | Phase 1 | Childhood Cancer | Dec 2030 |
| Han weidong | Anti-PD-1 antibody PD-1 inhibitor | PDCD1 | Phase 1 | Malignancies Multiple | – |
| Amal Therapeutics | BI 754091 PD-1 inhibitor | PDCD1 | Phase 1 | Colorectal Cancer | – |
| Formycon | FYB206 PD-1 inhibitor (anti-PD-1 antibody) | PDCD1 | Phase 1 | Melanoma, Stage II | – |
| invoX Pharma | Pembrolizumab (FS120) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Advanced Cancer | – |
| Chen Xiaozhong | Penplimab Injection PD-1 inhibitor | PDCD1 | Phase 1 | Metastatic Nasopharyngeal Carcinoma | – |
| Binhui Biopharmaceutical | Pucotenlimab (HX008) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Solid Tumor; Melanoma | – |
| Fujian Haixi Pharmaceuticals | Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Solid Tumor | – |
Melanoma (51) Breast Cancer (45) Gastric Cancer (44) Head and Neck Squamous Cell Carcinoma (43) Hepatocellular Carcinoma (41) Colorectal Cancer (41) Nasopharyngeal Carcinoma (41) Non Small Cell Lung Cancer (35) Non-small Cell Lung Cancer (35) Esophageal Squamous Cell Carcinoma (35) Non-Small Cell Lung Cancer (29) Cervical Cancer (26)
mixed (70), antibody (58), small molecule (58), protein or peptide (10), other (8)
Tianjin Medical University Cancer Institute and Hospital (8) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) Sun Yat-sen University (8) Fudan University (6) Ruijin Hospital (6) Akeso (5) Second Affiliated Hospital, Zhejiang University, School of Medicine (5) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) Sichuan Baili Pharmaceutical (3) Innovent Biologics (Suzhou) (3) Shanghai Henlius Biotech (3) Peking University Cancer Hospital & Institute (3) Sixth Affiliated Hospital, Sun Yat-sen University (3) AstraZeneca (3) Shanghai Zhongshan Hospital (3) Shenyang Sunshine Pharmaceutical (3) Tongji Hospital (3) Regeneron Pharmaceuticals (2) West China Hospital (2) Ono Pharmaceutical (2)
CTLA4 (30) CD274 (26) VEGFA (6) LAG3 (5) KDR (3) HAVCR2 (2) IL2 (2) TIGIT (2) ERBB2 (2) OPRM1 (2) IL2RA (2) GLP1R (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.